It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Extensive heterogeneity in autism spectrum disorder (ASD) has hindered the characterization of consistent biomarkers, which has led to widespread negative results. Isolating homogenized subtypes could provide insight into underlying biological mechanisms and an overall better understanding of ASD. A total of 1093 participants from the population-based “Healthy Brain Network” cohort (Child Mind Institute in the New York City area, USA) were selected based on score availability in behaviors relevant to ASD, aged 6–18 and IQ >= 70. All participants underwent an unsupervised clustering analysis on behavioral dimensions to reveal subgroups with ASD traits, identified by the presence of social deficits. Analysis revealed three socially impaired ASD traits subgroups: (1) high in emotionally dysfunctional traits, (2) high in ADHD-like traits, and (3) high in anxiety and depressive symptoms. 527 subjects had good quality structural MRI T1 data. Site effects on cortical features were adjusted using the ComBat method. Neuroimaging analyses compared cortical thickness, gyrification, and surface area, and were controlled for age, gender, and IQ, and corrected for multiple comparisons. Structural neuroimaging analyses contrasting one combined heterogeneous ASD traits group against controls did not yield any significant differences. Unique cortical signatures, however, were observed within each of the three individual ASD traits subgroups versus controls. These observations provide evidence of ASD traits subtypes, and confirm the necessity of applying dimensional approaches to extract meaningful differences, thus reducing heterogeneity and paving the way to better understanding ASD traits.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Université Paris-Saclay, Neurospin, Institut Joliot, CEA, Gif-sur-Yvette, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535)
2 Université Paris-Saclay, Neurospin, Institut Joliot, CEA, Gif-sur-Yvette, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535); 3 rue Joliot-Curie, CNRS-Centrale Supélec, Gif-sur-Yvette, France (GRID:grid.460789.4)
3 Université Paris-Saclay, Neurospin, Institut Joliot, CEA, Gif-sur-Yvette, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535); University of Paris-Est Créteil, APHP, Mondor Univ. Hospitals, DMU IMPACT, INSERM, U955, Translational Neuropsychiatry Team, Créteil, France (GRID:grid.460789.4)
4 Université Paris-Saclay, Neurospin, Institut Joliot, CEA, Gif-sur-Yvette, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535); University of Geneva, Faculty of Medicine, Geneva, Switzerland (GRID:grid.8591.5) (ISNI:0000 0001 2322 4988)